Armata Pharmaceuticals (ARMP) vs Voyager Therapeutics (VYGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Armata Pharmaceuticals (ARMP) has outperformed Voyager Therapeutics (VYGR) over the past year, gaining 21.3% versus a loss of 47.8%. Over five years, ARMP leads with a +10.4% price change compared with -39.8% for VYGR. Voyager Therapeutics is the larger company by market cap ($152.2 million vs $141.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARMP | VYGR |
|---|---|---|
| Share price | $3.81 | $2.47 |
| Market cap | $141.66M | $152.20M |
| 1-day change | -1.04% | +0.41% |
| YTD return | -39.33% | -37.15% |
| 1-year return | +21.34% | -47.78% |
| 5-year return | +10.43% | -39.76% |
| EPS (TTM) | $-5.29 | $-1.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.34 | $5.55 |
| 52-week low | $3.09 | $2.39 |
| Distance from 52-week high | -76.68% | -55.50% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +359.32% | +502.83% |
| Average volume | 210.93K | 566.47K |
| Shares outstanding | 37.18M | 61.62M |
| Employees | 61 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARMP has outperformed VYGR by 69.1 percentage points over the past year.
About Armata Pharmaceuticals
ARMP stock →Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 61 employees
About Voyager Therapeutics
VYGR stock →Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
ARMP vs VYGR FAQ
Which is bigger, Armata Pharmaceuticals or Voyager Therapeutics?
Voyager Therapeutics (VYGR) is larger, with a market capitalization of $152.20M compared with $141.66M for Armata Pharmaceuticals (ARMP).
Which stock has performed better over the past year, ARMP or VYGR?
ARMP returned +21.34% over the past 12 months, compared with -47.78% for VYGR (price return, excluding dividends). Past performance does not predict future results.
Are Armata Pharmaceuticals and Voyager Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.